DOCSLIB.ORG

Proteomics of Lipid Accumulation and DGAT Inhibition in Hepg2 Liver Carcinoma Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proteomics of Lipid Accumulation and DGAT Inhibition in Hepg2 Liver Carcinoma Cells Proteomics of lipid accumulation and DGAT inhibition in HepG2 liver carcinoma cells. By Bhumika Bhatt-Wessel A thesis submitted to Victoria University of Wellington in fulfilment of the requirement for the degree of Doctor of Philosophy In Cell and Molecular Biology. Victoria University of Wellington 2017. i ABSTRACT Non-alcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome in the liver. It is marked by hepatocyte accumulation of triacylglycerol (TAG) rich lipid droplets. In some patients, the disease progresses to non-alcoholic steatohepatitis (NASH), characterized by cellular damage, inflammation and fibrosis. In some cases, cirrhosis and liver failure may occur. However, the pathogenesis of NAFLD is still unclear. The present project is based on the hypothesis that hepatocytes are equipped with mechanisms that allow them to manage lipid accumulation to a certain extent. Continued or increased lipid accumulation beyond this triggers molecular mechanisms such as oxidative stress, lipid peroxidation and cell death that aggravate the condition and cause disease progression. The aim of this project is to study the effects of lipid accumulation on the cells using proteomics approach to identify proteins involved in the disease progression. A cell culture model was used in the study. HepG2 cells, a human liver carcinoma cell line, were treated with a mixture of fatty acids (FA) to induce lipid accumulation. The lipid accumulation in HepG2 cells was measured with Oil red O assay and the effect of lipid accumulation on the proliferation of the cells was measured using an MTT cell proliferation assay. HepG2 cells treated with 1 mM FA mixture for 6 hours induced lipid accumulation 1.4 times of control with 90% of cell proliferation capacity of the control cells. The final and the only committed step in TAG biosynthesis is catalysed by acyl-CoA diacylglycerol acyltransferase (DGAT) enzymes. To investigate if limiting lipid accumulation in HepG2 cells would prevent molecular mechanisms of pathogenesis, inhibition of DGAT by small molecule inhibitors was performed. Among the three DGAT inhibitors (A922500, PF06424439 and PF04620110) tested, PF04620110 reduced the lipid accumulation to 1.2 fold of the control cells when they were treated with 100 µM of the inhibitor in the presence of 1 mM FA mixture for 6 h. Proteomic analyses were carried out for the control, FA-treated and inhibitor-treated cell groups to identify protein changes in the abundance. Functional analyses of the changed proteins identified suggest that lipid accumulation tends to adversely affect the functioning of the ER and the mitochondria. A complex interplay between the two organelles, possibly mediated by Ca2+ signalling may be vital in ensuring cell survival. PF04620110 was able to counter the FA induced changes in the abundance of some proteins involved in the i metabolic processes but it had limited effect on the ER chaperones whose abundance in the inhibitor-treated sample was comparable to that of the FA-treated sample. These data provided important information for future discoveries of biomarkers and molecular mechanisms involved in the progression of NAFLD. ii ACKNOWLEDGEMENTS The time spent working on this thesis has been a profound lesson in life summed up in three traits I had to use extensively - patience, resilience and fortitude. Patience to wait and not be tired of waiting, resilience in accepting unexpected outcomes and the fortitude to keep on going. I have been supported by the best of people in this journey and tested thoroughly by some. They have all helped me put the best of me in this work. Thank you to my supervisors Dr. Bill Jordan and Prof. John Miller for the encouragement, support and advice – this project would not have been possible without your help. Dr Lifeng Peng, my primary supervisor, has introduced me to proteomics and my work is a reflection of her training; thank you for your critiques and support with the LC-MS/MS that is at the heart of this work. The introduction in this thesis has excerpts from the manuscript of a review Dr. Peng and I have worked on. Her feedback has improved the quality of the work and I hope the review will be published soon. I must acknowledge Dr. Ian Vorster for the help with the MS analysis of A922500 and Dr. Christine Stockum and Sarah Corinder who initiated me into the lab and helped build my skills in Western blotting and tissue culture respectively. Thank you Leticia Castro for keeping a constant vigil against mycoplasma and, along with Remi Schneider, trying your luck at growing HepG2 cells when everything seemed to fail. A special thanks to Sushila Pillai - the confocal microscopy guru who has helped me with the imaging of immunolabelled cells. Thank you Dr. Lisa Woods for your insight into biostatistics. Over the course of this PhD, this beautiful city has become my home and the amazing friends I have made are the best surrogate family I could hope for. Nishad, Karan, Jasmine, Christina, Rose, Rosie, Remi, Dinido and the whole Chiasma crew – you guys are all right! There are perhaps not enough words to express the deep gratitude and love for my partner Ronald Wessel who has been as much part of this PhD as I have. He’s the only bridge engineer I know who can talk about lipid accumulation in the liver like he knows it. At the end of the day, I hope I can make my parents and mota mummy proud and fulfil the aspirations they have for me. iii TABLE OF CONTENTS ACKNOWLEDGEMENTS .............................................................................................................. iii LIST OF FIGURES ......................................................................................................................... ix LIST OF TABLES .......................................................................................................................... xii CHAPTER 1: INTRODUCTION ...................................................................................................... 1 1.1. Conception of this project................................................................................................... 1 1.2. Prevalence of non-alcoholic fatty liver disease .................................................................. 1 1.3. Progression from NAFLD to NASH ...................................................................................... 1 1.4. Factors affecting disease progression ................................................................................. 3 1.5. Molecular mechanism of disease progression ................................................................... 4 1.5.1. First hit: Accumulation of triglycerides in lipid droplets .............................................. 4 1.5.2. ER stress ....................................................................................................................... 5 1.5.3. Mitochondrial dysfunction ........................................................................................... 6 1.6. Role of DGATs in triglyceride synthesis .............................................................................. 7 1.6.1. DGAT genes .................................................................................................................. 7 1.6.2. Membrane topology .................................................................................................. 10 1.6.3. Source of substrate .................................................................................................... 11 1.6.4. DGAT Inhibitors .......................................................................................................... 12 1.7. Models used to study NAFLD ............................................................................................ 13 1.7.1. Clinical studies in humans .......................................................................................... 13 1.7.2. Animal models of NAFLD ........................................................................................... 14 1.7.3. Cell-culture based models.......................................................................................... 15 1.8. Proteomics approach to lipid accumulation ..................................................................... 15 1.8.1. Separation of peptides and mass spectrometry ........................................................ 16 1.8.2. Peptide sequencing and identification of proteins .................................................... 18 1.8.3. Quantitative proteomics ............................................................................................ 19 1.9. Aims of the thesis .............................................................................................................. 21 CHAPTER 2: MATERIALS & METHODS ...................................................................................... 22 2.1 Materials ............................................................................................................................ 22 2.2 Cell culture ......................................................................................................................... 23 iv 2.3 Lipid accumulation in HepG2 cells ...................................................................................... 24 2.3.1. Preparation of fatty-acid stock solutions ................................................................... 24 2.3.2. Optimization of treatment conditions to induce lipid accumulation ......................... 24 2.3.3. Quantification
Load more

Recommended publications
  • SLC44A1 Transport of Choline and Ethanolamine in Disease
    SLC44A1 Transport of Choline and Ethanolamine in Disease by Adrian Taylor A Thesis presented to The University of Guelph In partial fulfilment of requirements for the degree of Doctor of Philosophy in Human Health and Nutritional Sciences Guelph, Ontario, Canada © Adrian Taylor, April, 2019 ABSTRACT SLC44A1 TRANSPORT OF CHOLINE AND ETHANOLAMINE IN DISEASE Adrian Taylor Advisor(s): University of Guelph, 2019 Marica Bakovic Choline and ethanolamine are important molecules required for the de novo synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) via the Kennedy pathway. Additionally, these two molecules are vital for maintaining both muscular and neurological function. The goal of this thesis was to gain insight into PC and PE metabolism with the use of unique metabolic disturbances ranging from obesity and genetic mutations in neurodegenerative disease. Firstly, the protective effects of choline supplementation on muscular function were investigated within the Pcyt2+/- mouse model. In Pcyt2+/- mice, substrate flow through the CDP-ethanolamine branch of the Kennedy pathway was diminished resulting in triacylglycerol (TAG) accumulation and obesity. Supplemental choline improved muscle function by altering the expression of genes devoted to reducing TAG synthesis and restoring energy homeostasis. With this new insight about the role of choline in regulating metabolism, the cellular uptake mechanism of choline was then analyzed. Skin fibroblasts from two patients with homozygous mutations in the SLC44A1 gene suffering from Neurodegeneration with Brain Iron Accumulation (NBIA) were utilized. In these fibroblasts, SLC44A1 expression and choline uptake were drastically diminished. Moreover, PC levels were unaffected while PE levels were diminished relative to control, an indication of perturbed phospholipid homeostasis.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Identification of Key Candidate Genes and Molecular Pathways in White Fat
    Pan et al. Human Genomics (2019) 13:55 https://doi.org/10.1186/s40246-019-0239-x PRIMARY RESEARCH Open Access Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology Yuyan Pan, Jiaqi Liu* and Fazhi Qi* Abstract Background: Obesity—with its increased risk of obesity-associated metabolic diseases—has become one of the greatest public health epidemics of the twenty-first century in affluent countries. To date, there are no ideal drugs for treating obesity. Studies have shown that activation of brown adipose tissue (BAT) can promote energy consumption and inhibit obesity, which makes browning of white adipose tissue (WAT) a potential therapeutic target for obesity. Our objective was to identify genes and molecular pathways associated with WAT and the activation of BAT to WAT browning, by using publicly available data and computational tools; this knowledge might help in targeting relevant signaling pathways for treating obesity and other related metabolic diseases. Results: In this study, we used text mining to find out genes related to brown fat and white fat browning. Combined with biological process and pathway analysis in GeneCodis and protein-protein interaction analysis by using STRING and Cytoscape, a list of high priority target genes was developed. The Human Protein Atlas was used to analyze protein expression. Candidate drugs were derived on the basis of the drug-gene interaction analysis of the final genes. Our study identified 18 genes representing 6 different pathways, targetable by a total of 33 drugs as possible drug treatments. The final list included 18 peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, 4 beta 3 adrenoceptor (β3-AR) agonists, 1 insulin sensitizer, 3 insulins, 6 lipase clearing factor stimulants and other drugs.
    [Show full text]
  • A Clinicopathological and Molecular Genetic Analysis of Low-Grade Glioma in Adults
    A CLINICOPATHOLOGICAL AND MOLECULAR GENETIC ANALYSIS OF LOW-GRADE GLIOMA IN ADULTS Presented by ANUSHREE SINGH MSc A thesis submitted in partial fulfilment of the requirements of the University of Wolverhampton for the degree of Doctor of Philosophy Brain Tumour Research Centre Research Institute in Healthcare Sciences Faculty of Science and Engineering University of Wolverhampton November 2014 i DECLARATION This work or any part thereof has not previously been presented in any form to the University or to any other body whether for the purposes of assessment, publication or for any other purpose (unless otherwise indicated). Save for any express acknowledgments, references and/or bibliographies cited in the work, I confirm that the intellectual content of the work is the result of my own efforts and of no other person. The right of Anushree Singh to be identified as author of this work is asserted in accordance with ss.77 and 78 of the Copyright, Designs and Patents Act 1988. At this date copyright is owned by the author. Signature: Anushree Date: 30th November 2014 ii ABSTRACT The aim of the study was to identify molecular markers that can determine progression of low grade glioma. This was done using various approaches such as IDH1 and IDH2 mutation analysis, MGMT methylation analysis, copy number analysis using array comparative genomic hybridisation and identification of differentially expressed miRNAs using miRNA microarray analysis. IDH1 mutation was present at a frequency of 71% in low grade glioma and was identified as an independent marker for improved OS in a multivariate analysis, which confirms the previous findings in low grade glioma studies.
    [Show full text]
  • Comparative Biochemistry and Physiology, Part D, Vol. 5, Pp. 45-54 (2010)
    Comparative genomics and proteomics of vertebrate diacylglycerol acyltransferase (DGAT), acyl CoA wax alcohol acyltransferase (AWAT) and monoacylglycerol acyltransferase (MGAT) Author Holmes, Roger S Published 2010 Journal Title Comparative Biochemistry and Physiology, Part D DOI https://doi.org/10.1016/j.cbd.2009.09.004 Copyright Statement © 2010 Elsevier. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version. Downloaded from http://hdl.handle.net/10072/36786 Griffith Research Online https://research-repository.griffith.edu.au Comparative Biochemistry and Physiology, Part D, Vol. 5, pp. 45-54 (2010) COMPARATIVE GENOMICS AND PROTEOMICS OF VERTEBRATE DIACYLGLYCEROL ACYLTRANSFERASE (DGAT), ACYL CoA WAX ALCOHOL ACYLTRANSFERASE (AWAT) AND MONOACYLGLYCEROL ACYLTRANSFERASE (MGAT) Roger S Holmes School of Biomolecular and Physical Sciences, Griffith University, Nathan 4111 Brisbane Queensland Australia Email: [email protected] Keywords: Diacylglycerol acyltransferase-Monoacylglycerol transferase-Human- Mouse-Opossum-Zebrafish-Genetics-Evolution-X chromosome Running Head: Genomics and proteomics of vertebrate acylglycerol acyltransferases ABSTRACT BLAT (BLAST-Like Alignment Tool) analyses of the opossum (Monodelphis domestica) and zebrafish (Danio rerio) genomes were undertaken using amino acid sequences of the acylglycerol acyltransferase (AGAT) superfamily. Evidence is reported for 8 opossum monoacylglycerol acyltransferase-like (MGAT) (E.C. 2.3.1.22) and diacylglycerol acyltransferase-like (DGAT) (E.C. 2.3.1.20) genes and proteins, including DGAT1, DGAT2, DGAT2L6 (DGAT2-like protein 6), AWAT1 (acyl-CoA wax alcohol acyltransferase 1), AWAT2, MGAT1, MGAT2 and MGAT3. Three of these genes (AWAT1, AWAT2 and DGAT2L6) are closely localized on the opossum X chromosome.
    [Show full text]
  • Supporting Table S3 for PDF Maker
    Supplemental Table S3. Annotation of identified proteins. Number of Sequence Accession Number of Theoretical Subcellular Number Locus ID Gene Name Protein Name Identified Coverage Theoretical pI Protein Family NSAF Number Amino Acid MW (Da) Location of TMD Peptides (%) (O08539) Myc box-dependent-interacting protein 1 O08539 BIN1_MOUSE BIN1 (Bridging integrator 1) (Amphiphysin-like protein) 3 10.5 588 64470 5 Nucleus other NONE 5.73E-05 (Amphiphysin II) (SH3-domain-containing protein 9) (O08547) Vesicle-trafficking protein SEC22b (SEC22 O08547 SC22B_MOUSE SEC22B 5 30.4 214 24609 8.5 Cytoplasm other 2 0.000262 vesicle-trafficking protein-like 1) (O08553) Dihydropyrimidinase-related protein 2 (DRP-2) O08553 DPYL2_MOUSE DPYSL2 5 19.4 572 62278 6.4 Cytoplasm enzyme NONE 7.85E-05 (ULIP 2 protein) O08579 EMD_MOUSE EMD (O08579) Emerin 1 5.8 259 29436 5 Nucleus other 1 8.67E-05 (O08583) THO complex subunit 4 (Tho4) (RNA and transcription O08583 THOC4_MOUSE THOC4 export factor-binding protein 1) (REF1-I) (Ally of AML-1 1 9.8 254 26809 11.2 Nucleus NONE 2.21E-05 regulator and LEF-1) (Aly/REF) O08585 CLCA_MOUSE CLTA (O08585) Clathrin light chain A (Lca) 2 4.7 235 25557 4.5 Plasma Membrane other NONE 0.000287 (O08600) Endonuclease G, mitochondrial precursor (EC O08600 NUCG_MOUSE ENDOG 4 23.1 294 32191 9.5 Cytoplasm enzyme NONE 0.000134 3.1.30.-) (Endo G) (O08638) Myosin-11 (Myosin heavy chain, smooth O08638 MYH11_MOUSE MYH11 8 6.6 1972 227026 5.5 Cytoplasm other NONE 3.13E-05 muscle isoform) (SMMHC) (O08648) Mitogen-activated protein kinase kinase
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • KONSTRUKTION VON ESCHERICHIA COLI PRODUKTIONSSTÄMMEN ZUR FERMENTATIVEN HERSTELLUNG VON SUCCINAT AUS GLYCERIN Stefan Söllner
    KONSTRUKTION VON ESCHERICHIA COLI PRODUKTIONSSTÄMMEN ZUR FERMENTATIVEN HERSTELLUNG VON SUCCINAT AUS GLYCERIN Von der Fakultät 4 (Energie-, Verfahrens- und Biotechnik) der Universität Stuttgart zur Erlangung der Würde eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigte Abhandlung Vorgelegt von Stefan Söllner aus Schweinfurt Hauptberichter: Prof. Dr. rer. nat. Ralf Mattes Mitberichter: Prof. Dr.-Ing. Ralf Takors Tag der mündlichen Prüfung: 29.02.2012 Institut für Industrielle Genetik Universität Stuttgart 2012 Vielen Dank! … Herrn Prof. Dr. R. Mattes danke ich für die Überlassung des interessanten Themas, des Arbeitsplatzes, für gelegentliches Aufmuntern und für die Erstellung des Erstgutachtens dieser Arbeit. … Herrn Prof. Dr. R. Takors danke ich für die freundliche Übernahme des Zweitgutachtens und für spannende Diskussionen. … Herrn Dr. Josef Altenbuchner danke ich für die praktische Betreuung dieser Arbeit, für diverse Einladungen zu Grillfesten und ganz besonders für die intensive Durchsicht des Manuskriptes!!! … Herrn Dr. Martin Siemann-Herzberg danke ich für die motivierende, überschwängliche Begeisterung, die meine Ideen und Ergebnisse bei deren Besprechung jedesmal auslösten. … Herrn Prof. Dr. Reuss danke ich für die Initiierung des Projektes lange vor meiner Zeit. … Meinen Kollegen und Exkollegen danke ich für die gute Zusammenarbeit, das abwechslungsreiche Arbeitsklima sowie die vielen fachlichen und nichtfachlichen Gespräche, welche die Arbeit immer spannend gestalteten. Vor allem danke ich für das Verständnis für die von mir durchgeführten, absolut notwendigen, regelmäßigen Arbeitskontrollen. … Frau Dr. Anne Völker hat mir die Integration zu Beginn meines Aufenthaltes am IIG sehr erleichtert. Herzlichen Dank dafür! … Herrn Kambiz Morabbi Heravi danke ich recht herzlich für die Einladung ans National Institute of Genetic Engineering and Biotechnology in Teheran, Iran und für die internationale Freundschaft.
    [Show full text]
  • Discovery of Novel Biomarkers for Atherosclerotic Aortic Aneurysm
    www.nature.com/scientificreports There are amendments to this paper OPEN Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression Hiroaki Yagi1,6, Mitsuhiro Nishigori1,2,6, Yusuke Murakami2,6, Tsukasa Osaki1, Sayaka Muto2,4, Yutaka Iba3, Kenji Minatoya3, Yoshihiko Ikeda4, Hatsue Ishibashi-Ueda4, Takayuki Morisaki5, Hitoshi Ogino3, Hiroshi Tanaka3, Hiroaki Sasaki3, Hitoshi Matsuda3 & Naoto Minamino1,2* Since aortic aneurysms (AAs) are mostly asymptomatic, but they have a high mortality rate upon rupture, their detection and progression evaluation are clinically important issues. To discover diagnostic biomarkers for AA, we performed proteome analysis of aortic media from patients with thoracic atherosclerotic AA (TAAA), comparing protein levels between the aneurysm and normal tissue areas. After hierarchical clustering analysis of the proteome analysis data, tissue samples were classifed into three groups, regardless of morphological features. This classifcation was shown to refect disease progression stage identifed by pathological examination. This proteomics-based staging system enabled us to identify more signifcantly altered proteins than the morphological classifcation system. In subsequent data analysis, Niemann-Pick disease type C2 protein (NPC2) and insulin-like growth factor-binding protein 7 (IGFBP7) were selected as novel biomarker candidates for AA and were compared with the previously reported biomarker, thrombospondin 1 (THBS1). Blood concentrations of NPC2 and IGFBP7 were signifcantly increased, while THBS1 levels were decreased in TAAA and abdominal atherosclerotic AA patients. Receiver operating characteristic analysis of AA patients and healthy controls showed that NPC2 and IGFBP7 have higher specifcity and sensitivity than THBS1. Thus, NPC2 and IGFBP7 are promising biomarkers for the detection and progression evaluation of AA.
    [Show full text]
  • Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus–Positive and Human Papillomavirus–Negative Head/Neck and Cervical Cancers
    Research Article Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus–Positive and Human Papillomavirus–Negative Head/Neck and Cervical Cancers Dohun Pyeon,1,2 Michael A. Newton,3 Paul F. Lambert,1 Johan A. den Boon,1,2 Srikumar Sengupta,1,2 Carmen J. Marsit,6 Craig D. Woodworth,7 Joseph P. Connor,4 Thomas H. Haugen,8 Elaine M. Smith,9 Karl T. Kelsey,6 Lubomir P. Turek,8 and Paul Ahlquist1,2,5 1McArdle Laboratory for Cancer Research; 2Institute for Molecular Virology; Departments of 3Statistics and of Biostatistics and Medical Informatics and 4Obstetrics and Gynecology; 5Howard Hughes Medical Institute, University of Wisconsin-Madison, Madison, Wisconsin; 6Departments of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts; 7Department of Biology, Clarkson University, Potsdam, New York; 8Department of Pathology, Veterans Affairs Medical Center; and 9Department of Epidemiology, University of Iowa, Iowa City, Iowa Abstract lower female reproductive tract, penis, and anus (1). In particular, Human papillomaviruses (HPV) are associated with nearly all high-risk HPVs are associated with nearly all cervical cancers, a cervical cancers, 20% to 30% of head and neck cancers (HNC), leading cause of cancer death in women worldwide despite the and other cancers. Because HNCs also arise in HPV-negative effectiveness in developed countries of screening for early patients, this type of cancer provides unique opportunities to detection of precancerous lesions (1). Prophylactic HPV vaccines define similarities and differences of HPV-positive versus HPV- should eventually reduce infections by the most prevalent high-risk HPVs, but do not cover all high-risk HPVs.
    [Show full text]
  • Supplementary Material Table of Contents
    Supplementary M aterial Table of Contents 1 - Online S u pplementary Methods ………………………………………………...… . …2 1.1 Study population……………………………………………………………..2 1.2 Quality control and principal component analysis …………………………..2 1.3 Statistical analyses………………………………………… ………………...3 1.3.1 Disease - specific association testing ……………………………… ..3 1.3.2 Cross - phenotype meta - analysis …………………………………… .3 1.3.3 Model search ……………………………………………………… .4 1.3.4 Novelty of the variants …………………………………………… ..4 1.3.5 Functional Enrichment Analy sis ………………………………… ...4 1.3.6 Drug Target Enrichment Analysis ………………………………… 5 2 - Supplementary Figures………………………………………...………………… . …. 7 3 - Members of the Myositis Genetics Consortium (MYOGEN) ……………………. ..16 4 - Members of the Scleroderma Genetics Consortium ………………… ……………...17 5 - Supplementary References………………………………………………………… . .18 6 - Supplementary Tables………………………………………………………… . ……22 1 Online supplementary m ethods Study population This study was conducted using 12,132 affected subjects and 23 ,260 controls of European des cent population and all of them have been included in previously published GWAS as summarized in Table S1. [1 - 6] Briefly, a total of 3,255 SLE cases and 9,562 ancestry matched controls were included from six countrie s across Europe and North America (Spain, Germany, Netherlands, Italy, UK, and USA). All of the included patients were diagnosed based on the standard American College of Rheumatology (ACR) classification criteria. [7] Previously described GWAS data from 2,363 SSc cases and 5,181 ancestry
    [Show full text]
  • As a Risk Gene for Schizophrenia X Chen Et Al
    Molecular Psychiatry (2011) 16, 1117–1129 & 2011 Macmillan Publishers Limited All rights reserved 1359-4184/11 www.nature.com/mp ORIGINAL ARTICLE GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5)asa risk gene for schizophrenia X Chen1,2, G Lee1, BS Maher1, AH Fanous1,3,4, J Chen1, Z Zhao5, A Guo5, E van den Oord1,6, PF Sullivan7, J Shi8, DF Levinson8, PV Gejman9, A Sanders9, J Duan9, MJ Owen10, NJ Craddock10, MC O’Donovan10, J Blackman10, D Lewis10, GK Kirov10, W Qin11, S Schwab11, D Wildenauer11, K Chowdari12, V Nimgaonkar12, RE Straub13, DR Weinberger13, FA O’Neill14, D Walsh15, M Bronstein16, A Darvasi16, T Lencz17, AK Malhotra17, D Rujescu18, I Giegling18, T Werge19, T Hansen19, A Ingason19, MM No¨ethen20, M Rietschel21,22, S Cichon20,23, S Djurovic24, OA Andreassen24, RM Cantor25, R Ophoff 25,26, A Corvin27, DW Morris27, M Gill27, CN Pato28, MT Pato28, A Macedo29, HMD Gurling30, A McQuillin30, J Pimm30, C Hultman31, P Lichtenstein31, P Sklar32,33, SM Purcell32,33, E Scolnick32,33, D St Clair 34, DHR Blackwood35 and KS Kendler1,2 and the GROUP investigators, the International Schizophrenia Consortium36 1Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA; 2Department of Molecular and Human Genetics, Virginia Commonwealth University, Richmond, VA, USA; 3Washington VA Medical Center, Washington, DC, USA; 4Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, USA; 5Departments
    [Show full text]